TCM
CSTL icon

Tradewinds Capital Management’s Castle Biosciences CSTL Stock Holding History

Tradewinds Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-5
Closed – – 438
2022
Q2 		$0 Hold
5
– – ﹤0.01% 500
2022
Q1 		$0 Buy
+5
New +$207 ﹤0.01% 788

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Tradewinds Capital Management's CSTL Position: Q3 2022 in Review

Tradewinds Capital Management sold out of Castle Biosciences (CSTL) in Q3 2022, closing a stake of 5 shares.

Tradewinds Capital Management first reported a position in CSTL in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 157 funds tracked by Wall St. Rank hold CSTL as of Q3 2022.

  • Tradewinds Capital Management reported no remaining Castle Biosciences position as of Q3 2022 after selling out during the quarter.
  • Tradewinds Capital Management sold 5 Castle Biosciences shares in Q3 2022.
  • Tradewinds Capital Management first reported a position in Castle Biosciences in Q1 2022 and held it in 2 quarters.
  • Tradewinds Capital Management's Castle Biosciences position peaked at $0 in Q2 2022.
  • 157 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2022.

Based on Tradewinds Capital Management's 13F filing for Q3 2022, filed 18 Oct 2022.